Core Viewpoint - Kangfang Biopharma has signed an exclusive commercialization rights agreement with Jichuan Pharmaceutical, granting Jichuan the exclusive rights to commercialize the drug Yixinning (Inusimab Injection) in mainland China, excluding Hong Kong, Macau, and Taiwan [1][2]. Group 1: Agreement Details - Kangfang Biopharma will receive a total of RMB 80 million (including tax) as an upfront licensing fee from Jichuan Pharmaceutical, along with potential milestone payments not exceeding RMB 10 million (including tax) [1]. - Jichuan Pharmaceutical will be responsible for the commercialization, promotion, and sales of Yixinning in the authorized market [1]. Group 2: Product Information - Yixinning (Inusimab Injection) is a novel PCSK9 monoclonal antibody developed by Kangfang Biopharma, approved for market in September 2024 for treating primary hypercholesterolemia and mixed dyslipidemia, including heterozygous familial hypercholesterolemia (HeFH) [2]. - The drug has been included in the latest National Medical Insurance Directory and is highly recommended in the 2025 edition of expert consensus on managing cardiovascular risks related to blood lipids [2]. - Yixinning works by specifically binding to PCSK9, blocking its interaction with LDL-R, thereby restoring LDL-R expression levels to enhance the clearance of LDL-C from plasma [2].

格隆汇2月3日丨康方生物(09926.HK)宣布，公司间接全资附属公司中山康方生物医药有限公司、康融东 方(广东)医药有限公司(以下合称「康方生物」)与湖北济川药业股份有限公司全资子公司济川药业集团 有限公司、江苏济源医药有限公司(以下合称「济川药业」)于近日签署《独占性商业化权益协议》，康 方生物授权济川药业在合作期限内，在中华人民共和国(不含香港、澳门特别行政区和台湾地区)拥有公 司自主开发并已获批上市的伊喜宁?(伊努西单抗注射液)的独家商业化权益。本次合作，康方生物将获 得由济川药业支付的人民币8,000万元(含税)授权费，以及最高不超过人民币1,000万元(含税)的里程碑付 款；济川药业将负责伊喜宁?在授权市场的商业化推广和销售。 ...